Clinical Trial Update: Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of MORAb-066 targeting tissue factor-expressing malignancies, including breast, pancreatic, colorectal, and non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• MORAb-066 (mORAb-066)

Snippet

Sponsor: Morphotek | Conditions: Breast Cancer, Pancreatic Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-03-29